Program
leronlimab
Also written as “PRO 140”, “Leronlimab (700mg)” and “350 mg leronlimab”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · COVID-19 · HIV Infections · Colorectal Neoplasms · Triple Negative Breast Neoplasms, led by CytoDyn.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CytoDyn | 201 open or running | phase 3since Jun 24, 2015 | May 10, 2005 | Jan 2028phase 2 · NCT06699836 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 10, 2005.
- Jun 24, 2015Phase 3 study in HIVNCT02483078 · 52 enrolled · United States, Puerto Rico
- Mar 29, 2016Phase 2 study in Graft vs Host DiseaseNCT02737306 · 11 enrolled · United States
- Jul 13, 2016Phase 3 study in HIVNCT02859961 · 562 enrolled · United States
- Nov 17, 2016Phase 3 study in Acquired Immunodeficiency SyndromeNCT02990858 · 43 enrolled
- Feb 5, 2019Phase 2 study in Triple Negative Breast NeoplasmsNCT03838367 · 10 enrolled · United States
- Apr 2, 2019Phase 3 study in HIV-1-infectionNCT03902522 · 6 enrolled · United States
- Nov 18, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04521114 · 87 enrolled · United States
- Mar 31, 2020Phase 2 study in COVID-19NCT04343651 · 86 enrolled · United States
- Apr 13, 2020Phase 2 study in COVID-19NCT04347239 · 484 enrolled · United States
- Jun 10, 2020Phase 2 study in Solid Tumor, AdultNCT04504942 · 16 enrolled · United States
- Dec 14, 2020Phase 2 study in COVID-19NCT04678830 · 56 enrolled · United States
- Jan 13, 2022Phase 3 study in HIV-1-infectionNCT05271370 · 56 enrolled · United States
- Feb 7, 2023Phase 2 study in Neoplasm MetastasisNCT05730673
- Nov 19, 2024Phase 2 study in Colorectal NeoplasmsNCT06699836 · 66 enrolled · United States
Ahead
- Jan 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06699836
TargetBeta
“A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), ”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule
Other programs on CCR5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Maravirocrule | GlaxoSmithKline | phase 4 | 26 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06699836Colorectal Neoplasms · United States | 2 | Active, not recruiting | Jan 2028 | 66 |
| NCT05730673Neoplasm Metastasis | 2 | Withdrawn | May 27, 2023 | 0 |
| NCT05271370HIV-1-infection · United States | 3 | Terminated | Jun 20, 2022 | 56 |
| NCT04678830COVID-19 · United States | 2 | Completed | Jun 5, 2021 | 56 |
| NCT04504942Solid Tumor, Adult · United States | 2 | Completed | Nov 7, 2021 | 16 |
| NCT04347239COVID-19 · United States | 2 | Completed | Oct 24, 2021 | 484 |
| NCT04343651COVID-19 · United States | 2 | Completed | Jul 21, 2020 | 86 |
| NCT04521114Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Dec 29, 2021 | 87 |
| NCT03902522HIV-1-infection · United States | 3 | Completed | May 18, 2020 | 6 |
| NCT03838367Triple Negative Breast Neoplasms · United States | 2 | Terminated | Jul 15, 2022 | 10 |
| NCT02990858Acquired Immunodeficiency Syndrome | 3 | Terminated | Jun 2022 | 43 |
| NCT02859961HIV · United States | 3 | Completed | Sep 16, 2020 | 562 |
| NCT02737306Graft vs Host Disease · United States | 2 | Terminated | Apr 14, 2021 | 11 |
| NCT02483078HIV · United States, Puerto Rico | 3 | Completed | Feb 2018 | 52 |
| NCT02355184Acquired Immunodeficiency Syndrome · United States | 2 | Terminated | Jun 2022 | 20 |
| NCT02175680Acquired Immunodeficiency Syndrome · United States | 2 | Completed | Feb 2, 2015 | 43 |
| NCT01272258HIV · United States | 2 | Withdrawn | Jan 2017 | 0 |
| NCT00642707HIV Infections · United States | 2 | Completed | Nov 2008 | 44 |
| NCT00613379HIV Infections · United States | 2 | Completed | Aug 2008 | 30 |
| NCT00110591HIV Infections · United States | 1 | Completed | Nov 7, 2005 | 20 |
How it is read
Names in the registry
- “PRO 140”, 9 entries
- “Leronlimab (700mg)”, 3 entries
- “350 mg leronlimab”, 2 entries
- “700 mg leronlimab”, 2 entries
- “PRO 140 (350 mg)”, 1 entry
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 3 studies
- COVID-19, 3 studies
- HIV Infections, 3 studies
- Colorectal Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.